Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

SNDX stock hub

Syndax Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SNDXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.9B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

SNDX

In the news

Latest news · SNDX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-189.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-29.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SNDX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001395937
Company name	Syndax Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	87164F105
Employees	298
Employees Change	28%
Employees Change Percent	10.37
Enterprise value	$1.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2016-03-03
Isin	US87164F1057
Last refreshed	2026-05-10
Market cap	$1.9B
Market cap category	Small-Cap
Price	$21.49
Price currency	USD
Rev Per Employee	728,771.81x
Sector	Healthcare
Sic	2834
Symbol	SNDX
Website	https://syndax.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.77%
EV/Sales	8.7x
FCF yield	-14.62%
P/B ratio	45.72x
P/S ratio	8.77x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-103.22%
EBITDA Margin	-103.22%
Gross margin	-23.17%
Gross Profit	$-50.3M
Gross Profit Growth Q	224.85%
Net Income	$-243.2M
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Pretax Margin	-112.19%
Profit Margin	-112.01%
Profit Per Employee	$-816,272
ROA	-25.17
Roa5y	-20.12
ROCE	-58
ROE	-189.5
Roe5y	-61.01
ROIC	-29.57

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	4.02%
Cagr1y	115.23%
Cagr3y	2.32%
Cagr5y	6.03%
EPS Growth Quarters	3
EPS Growth Years	1
Revenue Growth	396.72x
Revenue Growth Q	223.64x
Revenue Growth Quarters	4x
Revenue Growth Years	1x
Revenue Growth5 Y	169.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.39
Assets	$472.7M
Cash	$361.2M
Current Assets	$471.2M
Current Liabilities	$86.2M
Debt	$345.4M
Debt Equity	$8.3
Equity	$41.6M
Interest Coverage	-5.97
Liabilities	$431M
Long Term Assets	$1.5M
Long Term Liabilities	$344.9M
Net Cash	$15.9M
Net Cash By Market Cap	$0.83
Net Cash Growth	-90.7%
Net Debt Equity	$-0.38
Tangible Book Value	$41.6M
Tangible Book Value Per Share	$0.47
WACC	6.84

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.47
Inventory Turnover	10.45
Net Working Capital	$24.3M
Quick ratio	4.9
Working Capital	$385M
Working Capital Turnover	$0.52

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.5%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	48.31%
1Y total return	115.12%
200-day SMA	18.7
3Y total return	7.13%
50-day SMA	22.94
50-day SMA vs 200-day SMA	50over200
5Y total return	33.98%
All Time High	29.86
All Time High Change	-28.03%
All Time High Date	2023-02-02
All Time Low	3.39
All Time Low Change	533.92%
All Time Low Date	2018-12-26
ATR	1.11
Beta	0.41
Beta1y	-0.47
Beta2y	0.94
Ch YTD	2.29
High	21.86
High52	25.59
High52 Date	2026-03-25
High52ch	-16.02%
Low	20.48
Low52	8.58
Low52 Date	2025-05-15
Low52ch	150.47%
Ma50ch	-6.31%
Price vs 200-day SMA	14.94%
RSI	47.42
RSI Monthly	56.32
RSI Weekly	53.81
Sharpe ratio	1.49x
Sortino ratio	2.72
Total Return	-1.5%
Tr YTD	2.29
Tr1m	-12.78%
Tr1w	12.45%
Tr3m	2.29%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	4
Analyst Price Target Top	$40.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.59
Earnings Revenue Estimate	69,862,416x
Earnings Revenue Estimate Growth	248.58x
Operating Income	$-224.2M
Operating margin	-103.2
Price target	$41.45
Price Target Change	$92.88
Price Target Change Top	$88.46

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	75,100,251%
Float Percent	84.75%
Shares Insiders	0.65%
Shares Institutions	98.12%
Shares Out	88,610,027
Shares Qo Q	1.03%
Shares Yo Y	1.5%
Short Float	27.92%
Short Ratio	14.27
Short Shares	23.66

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-327.5M
Average Volume	1,720,807.65x
Bv Per Share	0.47
CAPEX	$-187,000
Ch10y	48.31
Ch1m	-12.78
Ch1w	12.45
Ch1y	115.1
Ch3m	2.29
Ch3y	7.13
Ch5y	33.98
Ch6m	42.89
Change	4.63%
Change From Open	4.63
Close	20.54
Days Gap	0
Depreciation Amortization	8,000
Dollar Volume	46,803,651.2
Earnings Date	2026-04-30
Earnings Time	amc
EBIT	$-224.2M
EBITDA	$-224.2M
EPS	$-2.79
F Score	2
FCF	$-278.4M
FCF EV Yield	-14.74x
FCF Per Share	$-3.14
Financing CF	20,664,000
Fiscal Year End	December
Founded	2,005
Income Tax	$-400,000
Investing CF	234,284,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	20.14
Ma150ch	6.7%
Ma20	21.93
Ma20ch	-2.02%
Net CF	-23,215,000
Next Earnings Date	2026-08-03
Open	20.54
Optionable	Yes
Position In Range	73.19
Post Close	21.49
Postmarket Change Percent	1.55
Postmarket Price	$21.82
Ppne	1,389,000
Price Date	2026-05-08
Ptbv Ratio	45.75
Relative Volume	1.27x
Revenue	217,174,000x
SBC By Revenue	22.64x
Share Based Comp	49,177,000
Tax By Revenue	-0.18x
Tr6m	42.89%
Us State	New York
Volume	2,177,927
Z Score	-2.81

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does SNDX pay a dividend?

Capital-return profile for this ticker.

Performance

SNDX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SNDX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+98.1%

Float: +84.8% of shares outstanding

Insider ownership

+0.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

SNDX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.4

Neutral momentum band

Price vs 200-day MA

+14.9%

50/200-day relationship not available

Beta (5Y)

0.41

Less volatile than the market

Sharpe ratio

1.49

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SNDX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current SNDX stock rating?

Syndax Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SNDX analysis?

The full report lives at /stocks/SNDX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for SNDX?

The latest report frames SNDX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the SNDX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.